Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ponatinib - Takeda

Next Previous
Drug Profile

Ponatinib - Takeda

Alternative Names: AP-24534; AP24534 HCl; AP24534 hydrochloride; AP24534-HCL; Iclusig; Ponatinib hydrochloride

Latest Information Update: 30 Dec 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ARIAD Pharmaceuticals
  • Developer ARIAD Pharmaceuticals; Dana-Farber Cancer Institute; Incyte Corporation; Massachusetts General Hospital; Mayo Clinic; National Cancer Institute (USA); Otsuka Pharmaceutical; University of Birmingham; University of Colorado at Denver
  • Class Antineoplastics; Benzamides; Imidazoles; Piperazines; Pyridazines; Small molecules
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors; Fibroblast growth factor receptor antagonists; Fms-like tyrosine kinase 3 inhibitors; Platelet derived growth factor alpha receptor antagonists; Proto oncogene protein c ret inhibitors; Proto oncogene protein c-kit inhibitors; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Precursor cell lymphoblastic leukaemia-lymphoma; Chronic myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
  • Phase II Acute myeloid leukaemia; Biliary cancer; Gastrointestinal stromal tumours; Lung cancer; Squamous cell cancer; Thyroid cancer
  • Phase I/II Haematological malignancies; Solid tumours

Most Recent Events

  • 22 Nov 2019 Phase-I/II clinical trials in Haematological malignancies (In children, In neonates, In adolescents, Recurrent, Late-stage disease, Second-line therapy or greater) in Spain, Netherlands, Sweden, Belgium (PO) (NCT03934372)
  • 22 Nov 2019 Phase-I/II clinical trials in Solid tumours (In children, In neonates, In adolescents, Recurrent, Late-stage disease, Second-line therapy or greater) in Sweden, Spain, Netherlands, Belgium (PO) (NCT03934372)
  • 01 May 2019 Incyte Biosciences plans a phase I/II trial for Solid tumours and Haematological malignancies (In children, In neonates, In adolescents, Recurrent, Late-stage disease, Second-line therapy or greater) in July 2019 (PO, Tablet) (NCT03934372)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top